YTHDF2 interference suppresses the EMT of cervical cancer cells and enhances cisplatin chemosensitivity by regulating AXIN1
Authors:
- 30 April 2022
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 83 (5) , 1190-1200
Abstract
M6A reader YTH structural domain family 2 (YTHDF2) has been recognized to play an oncogenic role in numerous tumors, but its role in cervical cancer has not been extensively discussed yet. This paper was designed to explore the role of YTHDF2 in cervical cancer and identify its underlying mechanism. The expression of YTHDF2 was first determined in cervical cancer cells by quantitative reverse‐transcription polymerase chain reaction and western blot. Then, the migration, invasion, and epithelial–mesenchymal transition (EMT) process were observed in YTHDF2‐knockdown Hela cells using wound healing, transwell and immunofluorescence assays. The cisplatin chemosensitivity of Hela cells was also investigated by assessing cell activity with cell counting kit‐8 and TUNEL (terminal deoxynucleotidyl transferase‐mediated dUTP nick end labeling). After MeRIP‐Seq assay and actinomycin D treatment to confirm the binding relationship between YTHDF2 and AXIN1, the migration, invasion, EMT process, and cisplatin chemosensitivity were assessed again in Hela cells silenced by YTHDF2 and AXIN1 or treated with Wnt agonist. YTHDF2 was increased in cervical cancer cells, and depletion of YTHDF2 led to reduced migration, invasion and EMT process but enhanced chemosensitivity of cisplatin in Hela cells. Furthermore, YTHDF2 could bind to and stabilize the expression of AXIN1. When the YTHDF2‐knockdown Hela cells were further transfected with AXIN1 knockdown or treated with Wnt agonist, the effects of YTHDF2 knockdown on the migration, invasion and EMT process were partially abolished, together with reduced cisplatin chemosensitivity. To sum up, we reported that YTHDF2 interference could suppress the EMT of cervical cancer cells and enhance cisplatin chemosensitivity by regulating AXIN1.Keywords
This publication has 24 references indexed in Scilit:
- Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancerJournal of Experimental & Clinical Cancer Research, 2017
- Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by inhibiting Wnt/β-catenin signalingBiochemical and Biophysical Research Communications, 2015
- EMT in cervical cancer: Its role in tumour progression and response to therapyCancer Letters, 2015
- AXIN1 and AXIN2 variants in gastrointestinal cancersCancer Letters, 2014
- Current and Potential Treatments for Cervical CancerCurrent Cancer Drug Targets, 2013
- Treatment of metastatic cervical cancer: Future directions involving targeted agentsCritical Reviews in Oncology/Hematology, 2013
- Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic ChangesPharmacological Reviews, 2012
- Short hairpin RNA targeting Twist1 suppresses cell proliferation and improves chemosensitivity to cisplatin in HeLa human cervical cancer cellsOncology Reports, 2012
- Wnt/β-Catenin Signaling and AXIN1 Regulate Apoptosis Triggered by Inhibition of the Mutant Kinase BRAF V600E in Human MelanomaScience Signaling, 2012
- Identification of Methylated Nucleosides in Messenger RNA from Novikoff Hepatoma CellsProceedings of the National Academy of Sciences, 1974